BioCryst Pharmaceuticals, Inc. (BCRX) — Financial statements
Income statement, balance sheet, and cash flow for BioCryst Pharmaceuticals, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 875↑94.1% | 451↑36.0% | 331↑22.4% | 271↑72.3% | 157 | |
| Cost of Revenue | 19↑52.8% | 12↑167.9% | 5↓29.3% | 7↓9.2% | 7 | |
| Gross Profit | 856↑95.3% | 438↑34.1% | 327↑23.7% | 264↑76.3% | 150 | |
| Operating Expenses | ||||||
| R&D Expenses | 166↓4.9% | 175↓19.4% | 217↓14.5% | 253↑21.3% | 209 | |
| General & Administrative Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 349↑31.0% | 266↑24.4% | 214↑34.2% | 159↑34.1% | 119 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 515↑16.8% | 441↑2.4% | 430↑4.3% | 413↑26.0% | 328 | |
| Total Costs & Expenses | 534↑17.8% | 453↑4.2% | 435↑3.8% | 419↑25.2% | 335 | |
| Operating Results | ||||||
| Operating Income | 341↑13508.9% | -3↑97.5% | -104↑30.1% | -148↑16.5% | -178 | |
| Depreciation & Amortization | 1↑11.5% | 1↓24.7% | 2↑15.2% | 1↑84.9% | 0.78 | |
| EBITDA | 348↑2614.3% | 13↑111.0% | -116↑19.1% | -144↓18.2% | -122 | |
| EBIT | 346↑2894.8% | 12↑109.8% | -118↑18.8% | -145↓18.6% | -123 | |
| Interest & Other Income | ||||||
| Net Interest Income | -68↑18.6% | -84↑9.4% | -92↑1.6% | -94↓58.6% | -59 | |
| Interest Income | 11↓27.7% | 15↓6.5% | 16↑207.7% | 5↑8169.4% | 0.06 | |
| Interest Expense | 79↓19.9% | 99↓9.0% | 108↑9.2% | 99↑67.1% | 59 | |
| Non-Operating Income | -5↑62.6% | -14↓198.8% | 14↑554.2% | -3↑94.3% | -55 | |
| Other Income / Expenses | -74↑12.8% | -84↑31.1% | -123↓27.7% | -96↓2246.5% | -4 | |
| Income Before Tax | 267↑407.5% | -87↑61.6% | -226↑7.4% | -244↓34.4% | -182 | |
| Income Tax Expense | 4↑83.2% | 2↑521.6% | 0.31↓88.7% | 3↑21.3% | 2 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | 264↑396.9% | -89↑60.8% | -227↑8.3% | -247↓34.3% | -184 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | 264↑396.9% | -89↑60.8% | -227↑8.3% | -247↓34.3% | -184 | |
| Bottom-Line Net Income | 264↑396.9% | -89↑60.8% | -227↑8.3% | -247↓34.3% | -184 | |
| EPS (Basic) | 1.26↑393.0% | -0.43↑63.6% | -1.18↑11.3% | -1.33↓29.1% | -1.03 | |
| EPS (Diluted) | 1.21↑381.4% | -0.43↑63.6% | -1.18↑11.3% | -1.33↓29.1% | -1.03 | |
| Weighted Average Shares | 210↑1.5% | 207↑7.5% | 192↑3.4% | 186↑3.8% | 179 | |
| Weighted Average Diluted Shares | 219↑5.7% | 207↑7.5% | 192↑3.4% | 186↑3.8% | 179 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.